Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer

Technology appraisal guidance
Reference number: TA263
Published: 22 August 2012

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): consultee and commentator comments on the ACD

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): Roche pharmaceuticals
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): Breakthrough Breast Cancer
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): Royal College of Nursing
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): Royal College of Physicians
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): Department of Health

This page was last updated: 04 July 2012